Profound Medical (PROF)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Image-guided Ablationsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 52/100 (HIGH), 11.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.26% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
- TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
- Profound Medical And 2 Canadian AI Healthcare Stocks To Watch
- Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education
- Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
- Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
- Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
- Profound Medical Announces Management Change
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation. — Front Med (Lausanne) 2026 PMID 42769889
- Photothermal-driven sequential immunotherapy overcomes resistance to PARP inhibition in Brca1-deficient triple-negative breast cancer. — Acta Pharm Sin B 2026 Sep PMID 42765032
- Unexpected Prolonged Apnea Following Succinylcholine in a Medically Complex Patient: A Case Report. — Cureus 2026 Aug PMID 42764859
- BBOX1 Deficiency Exacerbates Liver Fibrosis Through Carnitine Biosynthesis Disruption Rescued by Carnitine Supplementation. — Liver Int 2026 Oct PMID 42757697
- Single-cell insights into drug response and resistance in inflammatory bowel disease: cellular hallmarks and precision therapy. — J Crohns Colitis 2026 Sep 3 PMID 42753707
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Profound Medical.
Full PROF Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.